EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

European Urology

Volumn 71, Issue 4, 2017, Pages 630-642

  Cornford, Philip ^a   Bellmunt, Joaquim ^b,c   Bolla, Michel ^d   Briers, Erik ^e   De Santis, Maria ^f   Gross, Tobias ^g   Henry, Ann M ^h   Joniau, Steven ⁱ   Lam, Thomas B ^j,k   Mason, Malcolm D ^l   van der Poel, Henk G ^m   van der Kwast, Theo H ⁿ   Rouvière, Olivier ^o   Wiegel, Thomas ^p   Mottet, Nicolas ^q  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e Patients Advocate   (Belgium)

^f UNIVERSITY OF WARWICK   (United Kingdom)

^g UNIVERSITY OF BERN   (Switzerland)

^h ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j UNIVERSITY OF ABERDEEN   (United Kingdom)

^k ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^l VELINDRE CANCER CENTRE   (United Kingdom)

^m NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

^o EDOUARD HERRIOT HOSPITAL   (France)

^p UNIVERSITY HOSPITAL ULM   (Germany)

^q UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

more..

Author keywords

Castration resistant; Chemotherapy; EAU ESTRO SIOG Guidelines; Follow up; Hormonal therapy; Metastatic; Palliative; Prostate cancer; Relapse; Staging

Indexed keywords

ABIRATERONE ACETATE; ANTIANDROGEN; CABAZITAXEL; CHOLINE C 11; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; SIPULEUCEL T; TESTOSTERONE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; TAXOID; TISSUE EXTRACT;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CRYOSURGERY; HORMONAL THERAPY; HUMAN; MALE; METASTASIS; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATECTOMY; RECURRENCE RISK; TESTOSTERONE BLOOD LEVEL; ANALOGS AND DERIVATIVES; BRACHYTHERAPY; CARCINOMA; HIGH INTENSITY FOCUSED ULTRASOUND; PATHOLOGY; PROSTATE TUMOR; SALVAGE THERAPY; SECONDARY; TUMOR RECURRENCE;

ABIRATERONE ACETATE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARCINOMA; CRYOSURGERY; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PHENYLTHIOHYDANTOIN; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SALVAGE THERAPY; TAXOIDS; TISSUE EXTRACTS;

EID: 85014090415     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.08.002     Document Type: Article

References (101)

1. [1] Heidenreich, A., Bastian, P.J., Bellmunt, J., et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65 (2014), 467–479.
2. [2] Mottet, M., Bellmunt, J., Bolla, M., et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis and local treatment with curative intent. Eur Urol 71 (2017), 618–629.
3. [3] Oxford Centre for Evidence-Based Medicine – levels of evidence (March 2009). Centre for Evidence-Based Medicine Web site. http://www.cebm.net/index.aspx?o=1025.
4. [4] Amling, C.L., Bergstralh, E.J., Blute, M.L., Slezak, J.M., Zincke, H., Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol 165 (2001), 1146–1151.
5. [5] Roach, M. III, Hanks, G., Thames, H. Jr., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006), 965–974.
6. [6] Brockman, J.A., Alanee, S., Vickers, A.J., et al. Nomogram predicting prostate cancer-specific mortality for men with biochemical recurrence after radical prostatectomy. Eur Urol 67 (2015), 1160–1167.
7. [7] D'Amico, A.V., Moul, J., Carroll, P.R., Sun, L., Lubeck, D., Chen, M.H., Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004), S42–S46 discussion S46-7.
8. [8] Trock, B.J., Han, M., Freedland, S.J., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299 (2008), 2760–2769.
9. [9] Zumsteg, Z.S., Spratt, D.E., Romesser, P.B., et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol 67 (2015), 1009–1016.
10. [10] Rouviere, O., Vitry, T., Lyonnet, D., Imaging of prostate cancer local recurrences: why and how?. Eur Radiol 20 (2010), 1254–1266.
11. [11] Beresford, M.J., Gillatt, D., Benson, R.J., Ajithkumar, T., A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol) 22 (2010), 46–55.
12. [12] Ceci, F., Herrmann, K., Castellucci, P., et al. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging 41 (2014), 2222–2231.
13. [13] Treglia, G., Ceriani, L., Sadeghi, R., Giovacchini, G., Giovanella, L., Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med 52 (2014), 725–733.
14. [14] Abd-Alazeez, M., Ramachandran, N., Dikaios, N., et al. Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images. Prostate Cancer Prostatic Dis 18 (2015), 128–136.
15. [15] Mitchell, C.R., Lowe, V.J., Rangel, L.J., Hung, J.C., Kwon, E.D., Karnes, R.J., Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol 189 (2013), 1308–1313.
16. [16] Rybalov, M., Breeuwsma, A.J., Leliveld, A.M., Pruim, J., Dierckx, R.A., de Jong, I.J., Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-choline positron emission tomography in recurrent prostate cancer. World J Urol 31 (2013), 319–323.
17. [17] Pfister, D., Bolla, M., Briganti, A., et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol 65 (2014), 1034–1043.
18. [18] Wiegel, T., Lohm, G., Bottke, D., et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome–results of a retrospective study. Int J Radiat Oncol Biol Phys 73 (2009), 1009–1016.
19. [19] Goenka, A., Magsanoc, J.M., Pei, X., et al. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys 84 (2012), 112–118.
20. [20] Soto, D.E., Passarelli, M.N., Daignault, S., Sandler, H.M., Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients. Int J Radiat Oncol Biol Phys 82 (2012), 1227–1232.
21. [21] Shipley, W.U., Seiferheld, W., Lukka, H., et al. Report of NRG Oncology/RTOG 9601, a phase 3 trial in prostate cancer: anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) in patients following radical prostatectomy (RP) with pT2-3pN0 disease and an elevated PSA. Int J Radiat Oncol Biol Phys, 94, 2016, 3.
22. [22] Carrie, C., Hasbini, A., de Laroche, G., et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17 (2016), 747–756.
23. [23] Briganti, A., Wiegel, T., Joniau, S., et al. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol 62 (2012), 472–487.
24. [24] Chade, D.C., Eastham, J., Graefen, M., et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 61 (2012), 961–971.
25. [25] Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). EJC 45 (2009), 228–247.
26. [26] Ismail, M., Ahmed, S., Kastner, C., Davies, J., Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 100 (2007), 760–764.
27. [27] Pisters, L.L., Leibovici, D., Blute, M., et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 182 (2009), 517–525 discussion 525-7.
28. [28] Ahmad, I., Kalna, G., Ismail, M., et al. Prostate gland lengths and iceball dimensions predict micturition functional outcome following salvage prostate cryotherapy in men with radiation recurrent prostate cancer. PLoS One, 8, 2013, e69243.
29. [29] Chen, C.P., Weinberg, V., Shinohara, K., et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 86 (2013), 324–329.
30. [30] Yamada, Y., Kollmeier, M.A., Pei, X., et al. A phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy 13 (2014), 111–116.
31. [31] Lee, B., Shinohara, K., Weinberg, V., et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 67 (2007), 1106–1112.
32. [32] Burri, R.J., Stone, N.N., Unger, P., Stock, R.G., Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 77 (2010), 1338–1344.
33. [33] Crouzet, S., Murat, F.J., Pommier, P., et al. Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes. Radiother Oncol 105 (2012), 198–202.
34. [34] Ost, P., Bossi, A., Decaestecker, K., et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67 (2015), 852–863.
35. [35] Karnes, R.J., Murphy, C.R., Bergstralh, E.J., et al. Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. J Urol 193 (2015), 111–116.
36. [36] Rigatti, P., Suardi, N., Briganti, A., et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 60 (2011), 935–943.
37. [37] Studer, U.E., Collette, L., Whelan, P., et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 53 (2008), 941–949.
38. [38] van den Bergh, R.C., van Casteren, N.J., van den Broeck, T., et al. Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review. Eur Urol 69 (2016), 802–820.
39. [39] Bayoumi, A.M., Brown, A.D., Garber, A.M., Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92 (2000), 1731–1739.
40. [40] Nair, B., Wilt, T., MacDonald, R., Rutks, I., Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev, 2002, CD003506.
41. [41] Oefelein, M.G., Feng, A., Scolieri, M.J., Ricchiutti, D., Resnick, M.I., Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 56 (2000), 1021–1024.
42. [42] Morote, J., Planas, J., Salvador, C., Raventos, C.X., Catalan, R., Reventos, J., Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int 103 (2009), 332–335 discussion 335.
43. [43] Pickles, T., Hamm, J., Morris, W.J., Schreiber, W.E., Tyldesley, S., Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?. BJU Int 110 (2012), E500–E507.
44. [44] Seidenfeld, J., Samson, D.J., Hasselblad, V., et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132 (2000), 566–577.
45. [45] Crawford, E.D., Shore, N.D., Moul, J.W., et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology 83 (2014), 1122–1128.
46. [46] Tsushima, T., Nasu, Y., Saika, T., et al. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. Urol Int 66 (2001), 135–139.
47. [47] Iversen, P., Antiandrogen monotherapy: indications and results. Urology 60 (2002), 64–71.
48. [48] Smith, M.R., Goode, M., Zietman, A.L., McGovern, F.J., Lee, H., Finkelstein, J.S., Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 22 (2004), 2546–2553.
49. [49] Kunath, F., Grobe, H.R., Rucker, G., et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev, 6, 2014, CD009266.
50. [50] Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 (2000), 1491–1498.
51. [51] Schmitt, B., Bennett, C., Seidenfeld, J., Samson, D., Wilt, T., Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev, 2000, CD001526.
52. [52] Akaza, H., Hinotsu, S., Usami, M., et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115 (2009), 3437–3445.
53. [53] Niraula, S., Le, L.W., Tannock, I.F., Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol 31 (2013), 2029–2036.
54. [54] Sciarra, A., Salciccia, S., A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy?. Eur Urol 65 (2014), 905–906.
55. [55] Botrel, T.E., Clark, O., dos Reis, R.B., et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol, 14, 2014, 9.
56. [56] Brungs, D., Chen, J., Masson, P., Epstein, R.J., Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 17 (2014), 105–111.
57. [57] Hussain, M., Tangen, C.M., Berry, D.L., et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368 (2013), 1314–1325.
58. [58] Gravis, G., Fizazi, K., Joly, F., et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14 (2013), 149–158.
59. [59] Gravis, G., Boher, J.M., Joly, F., et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 70 (2016), 256–262.
60. [60] Sweeney, C.J., Chen, Y.H., Carducci, M., et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373 (2015), 737–746.
61. [61] James, N.D., Sydes, M.R., Clarke, N.W., et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387 (2016), 1163–1177.
62. [62] Smith, T.J., Bohlke, K., Lyman, G.H., et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33 (2015), 3199–3212.
63. [63] Collette, L., de Reijke, T.M., Schroder, F.H., Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 44 (2003), 182–189 discussion 189.
64. [64] Scher, H.I., Halabi, S., Tannock, I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008), 1148–1159.
65. [65] Smith, M.R., Boyce, S.P., Moyneur, E., Duh, M.S., Raut, M.K., Brandman, J., Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175 (2006), 136–139 discussion 139.
66. [66] Conde, F.A., Aronson, W.J., Risk factors for male osteoporosis. Urol Oncol 21 (2003), 380–383.
67. [67] Saylor, P.J., Smith, M.R., Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 181 (2009), 1998–2006 discussion 2007-8.
68. [68] Faris, J.E., Smith, M.R., Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 17 (2010), 240–246.
69. [69] Smith, M.R., Kabbinavar, F., Saad, F., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23 (2005), 2918–2925.
70. [70] Smith, M.R., Cook, R., Lee, K.A., Nelson, J.B., Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 117 (2011), 2077–2085.
71. [71] Crawford, E.D., Stone, N.N., Yu, E.Y., et al. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology 83 (2014), 664–669.
72. [72] Hussain, M., Wolf, M., Marshall, E., Crawford, E.D., Eisenberger, M., Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 12 (1994), 1868–1875.
73. [73] Taylor, C.D., Elson, P., Trump, D.L., Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11 (1993), 2167–2172.
74. [74] Ryan, C.J., Smith, M.R., de Bono, J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 (2013), 138–148.
75. [75] Ryan, C.J., Smith, M.R., Fizazi, K., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16 (2015), 152–160.
76. [76] Beer, T.M., Armstrong, A.J., Rathkopf, D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 (2014), 424–433.
77. [77] Kantoff, P.W., Schuetz, T.J., Blumenstein, B.A., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28 (2010), 1099–1105.
78. [78] Tannock, I.F., de Wit, R., Berry, W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004), 1502–1512.
79. [79] Eisenberger, M., Garrett-Mayer, E.S., Ou Yang, Y., de Wit, R., Tannock, I., Armstrong, A.J., A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC). J Clin Oncol, 25(Suppl), 2007 abstract 5058.
80. [80] Armstrong, A.J., Garrett-Mayer, E., de Wit, R., Tannock, I., Eisenberger, M., Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16 (2010), 203–211.
81. [81] Horgan, A.M., Seruga, B., Pond, G.R., et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol 5 (2014), 119–126.
82. [82] Kellokumpu-Lehtinen, P.L., Harmenberg, U., Joensuu, T., et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 14 (2013), 117–124.
83. [83] Parker, C., Nilsson, S., Heinrich, D., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369 (2013), 213–223.
84. [84] Hoskin, P., Sartor, O., O'Sullivan, J.M., et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 15 (2014), 1397–1406.
85. [85] Gillessen, S., Omlin, A., Attard, G., et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26 (2015), 1589–1604.
86. [86] Pezaro, C.J., Omlin, A., Lorente, D., et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 65 (2014), 270–273.
87. [87] Antonarakis, E.S., Lu, C., Wang, H., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 (2014), 1028–1038.
88. [88] Beer, T.M., Garzotto, M., Henner, W.D., Eilers, K.M., Wersinger, E.M., Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 91 (2004), 1425–1427.
89. [89] Ohlmann, C.H., Özgür, E., Wille, S., Engelmann, U., Heidenreich, A., Second-line chemotherapy with docetaxel for prostate-specific antigen relapse in men with hormone refractory prostate cancer previously treated with docetaxel based chemotherapy. Eur Urol Suppl, 5, 2006 abstract 289.
90. [90] de Bono, J.S., Oudard, S., Ozguroglu, M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376 (2010), 1147–1154.
91. [91] Resnick, M.J., Lacchetti, C., Bergman, J., et al. Prostate cancer survivorship care guideline: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 33 (2015), 1078–1085.
92. [92] de Bono, J.S., Logothetis, C.J., Molina, A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 (2011), 1995–2005.
93. [93] Fizazi, K., Scher, H.I., Molina, A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13 (2012), 983–992.
94. [94] Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
95. [95] Dy, S.M., Asch, S.M., Naeim, A., Sanati, H., Walling, A., Lorenz, K.A., Evidence-based standards for cancer pain management. J Clin Oncol 26 (2008), 3879–3885.
96. [96] Hartsell, W.F., Scott, C.B., Bruner, D.W., et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97 (2005), 798–804.
97. [97] Saad, F., Gleason, D.M., Murray, R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002), 1458–1468.
98. [98] Aapro, M., Abrahamsson, P.A., Body, J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19 (2008), 420–432.
99. [99] Smith, M.R., Saad, F., Coleman, R., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379 (2012), 39–46.
100. [100] Fizazi, K., Carducci, M., Smith, M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377 (2011), 813–822.
101. [101] Esper, P.S., Pienta, K.J., Supportive care in the patient with hormone refractory prostate cancer. Semin Urol Oncol 15 (1997), 56–64.